Research: SCHIPPER

Listed in Issue 199

Abstract

SCHIPPER, Centre for Neurotranslational Research and Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Cote St. Catherine Road, McGill University, Montreal, Quebec, Canada H3T 1E2. hyman.schipper@mcgill.ca reviewed the evidence of apolipoprotein E (apoE) in the neurobiology and epidemiology of Alzheimer disease (AD).

Background

Alzheimer disease (AD) is a common and devastating dementing illness for which there is no effective neuroprotective therapy or cure. The presence of the apolipoprotein E (apoE) epsilon4 allele is a well-established genetic modifier (risk factor) of sporadic AD.

Methodology

In this review, The authors provide an update on the implications of apoE for the neurobiology and epidemiology of AD.

Results

Moreover, recent evidence is adduced indicating that (i) many AD risk factors are potentially modifiable by adaptive lifestyle changes and pharmacotherapy and (ii) the potency of these modifiable AD determinants and responsiveness to intervention are often significantly impacted by the presence or absence of the epsilon4 allele.

Conclusion

Delineation of the influences of the APOE genotype on modifiable AD risk factors and prevention may spur consideration of APOE testing for presymptomatic individuals seeking to define their personal risk.

References

Schipper HM. Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment. [Review] Source Neurobiology of Aging. 32(5): 778-90. May 2011.

Munro Hall Clinic 2019

IJCA 2018 New Skyscraper

Scientific and Medical Network 2

Cycle India 2020

Walk on the Wide Side Trek Kenya 2020

Big Heart Bike Ride South Africa 2020

top of the page